About the Program
ImmunoEngineering is the application of engineering tools and principles to quantitatively study the immune system in health and disease and to develop new therapies or improve existing therapies by enhancing and modulating immune responses.
The Georgia Immunoengineering Consortium is a unique partnership between the Georgia Institute of Technology and Emory University that brings together engineers, chemists, physicists, computational scientists, immunologists and clinicians to collaboratively understand how the immune system works and find breakthrough solutions to improve the lives of individuals suffering from cancer, infectious diseases, autoimmune and inflammatory disorders (e.g. diabetes, lupus, multiple sclerosis, arthritis, fibrosis, asthma, inflammatory bowel disease etc.) as well as those undergoing regenerative therapies (e.g. transplantation, spinal cord injury, bone and cartilage repair etc.). Our objective is to catalyze Emory and Georgia Tech's strengths in immunology and bioengineering to translate discoveries that predict, recognize, prevent and treat human immunological/inflammatory based diseases.
The Vision of the Georgia Immunoengineering Consortium is to become the international leader in ImmunoEngineering science, technology, clinical translation and trainee development, and be recognized as such.
The Mission of the Georgia Immunoengineering Consortium is to create breakthrough engineering tools, methods and solutions for personalized and predictive health-care in individuals with particular focus on the following three Grand Challenges:
a. Ability to rapidly provide a comprehensive immunological status
b. Ability to quantitatively predict immune function and
c. Ability to better enhance and modulate the immune response
The Georgia Immunoengineering Consortium provides a collaborative foundation where the various Immunology focused research programs from Georgia Tech and Emory (e.g. The Center for ImmunoEngineering at Georgia Tech, The Emory Vaccine Center, The Lowance Center for Human Immunology, The Emory School of Medicine, The Department of Microbiology and Immunology as well as the Department of Pathology at Emory, Emory Children's Center and Pediatric Research Centers, The Winship Cancer Institute etc.) works together to provide engineering-driven clinical solutions to immune-dysfunction. The Georgia Immunoengineering Consortium researchers also works in collaboration with partners at the CDC as well as researchers at various colleges and universities around Georgia, the United States and the around the world.